

Georgia

Population 2018

4 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	3.2 (2.7–3.8)	80 (67–94)
HIV-positive TB incidence	0.066 (0.046–0.09)	1.6 (1.1–2.3)
MDR/RR-TB incidence ^{oo}	0.57 (0.45–0.7)	14 (11–18)
HIV-negative TB mortality	0.16 (0.15–0.18)	4 (3.6–4.4)
HIV-positive TB mortality	0.017 (0.011–0.025)	0.43 (0.28–0.61)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	12% (10–14)
Previously treated cases	31% (27–35)

TB case notifications, 2018

Total new and relapse	2 316
- % tested with rapid diagnostics at time of diagnosis	84%
- % with known HIV status	94%
- % pulmonary	80%
- % bacteriologically confirmed ^{ooo}	87%
- % children aged 0-14 years	4%
- % women	30%
- % men	66%
Total cases notified	2 590

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	73% (62–87)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	6% (5–7)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	45	2%
- on antiretroviral therapy	45	100%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	97%
- Previously treated cases	86%
Laboratory-confirmed cases*	MDR/RR-TB: 311, XDR-TB: 55
Patients started on treatment**	MDR/RR-TB: 323, XDR-TB: 55
MDR/RR-TB cases tested for resistance to second-line drugs	201

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	84%	2 351
Previously treated cases, excluding relapse, registered in 2017	64%	225
HIV-positive TB cases registered in 2017	70%	33
MDR/RR-TB cases started on second-line treatment in 2016	65%	339
XDR-TB cases started on second-line treatment in 2016	56%	55

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	31% (29–34)

TB financing, 2019

National TB budget (US\$ millions)	13
Funding source: 50% domestic, 63% international, <1% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2018




Legend:
■ Females
■ Males
 Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive
■ MDR/RR-TB
■ XDR-TB

Total budget (US\$ millions)



Legend:
■ Unfunded
■ Funded internationally
■ Funded domestically